Shows
Cures & CapitalEpisode 9 - Reflections and TakeawaysOver the past few months, we’ve had the chance to speak with some of the sharpest minds in the industry—thinkers and practitioners who have shaped how we understand drug innovation, R&D productivity, portfolio strategy, and other critical topics.In this episode, we bring together the major insights and lessons, highlighting patterns that emerged across the different conversations.We also spotlight the unique takeaways from each guest to help ensure these key learnings really stick. Whether you're an R&D leader, investor, innovator, or strategist, these insights will help you rethink how to crea...2025-05-0733 minCures & CapitalAaron Schacht on the pharmaceutical industry's grand challenge and managing R&D at scaleIn this episode, we talk to Aaron Schact, the CEO and Board Director at BiomEdit and former R&D leader at Eli Lilly and Elanco. We discuss how to improve biopharma's R&D productivity and the industry's "grand challenge", why R&D productivity is the mental model for managing R&D at scale, practical advice on how to approach and work with R&D productivity, and much more!If you want to connect with us - we would love to hear from you:Linkedin: https://www.linkedin.com/company/cures-capital-podcastIf you p...2025-04-2253 minCures & CapitalMatthias Krings on crafting winning biopharma strategies and smart decisionsIn this episode, our guest is Dr. Matthias Krings - a senior partner at Catenion, a biopharma strategy consulting firm.Matthias is a seasoned veteran in biopharma strategy.In this conversation, he shares his playbook for achieving success as a biopharma company.As critical pillars for biopharma success, we dive into strategy processes, decision-making, and effective R&D risk management.If you want to connect with us - we would love to hear from you:LinkedIn: https://www.linkedin.com/company/cures-capital-podcastYou can also watch the...2025-04-0749 minCures & CapitalStephan Christgau on applying the VC mindset in biotech & pharmaHow do venture capitalists think? And how do they define and create value in the life science industry?In this episode, we talk to Stephan Christgau, founding partner of Eir Ventures, about the VC mindset, investment decision-making and portfolio strategy. We dive into how VCs assess risk, balance high-stakes opportunities, and what could pharma and biotech companies learn from the VC way of doing things.If you want to connect with us - we would love to hear from you:Linkedin: https://www.linkedin.com/company/cures-capital-podcastIf you prefer to get...2025-03-201h 03Cures & CapitalMurray Aitken's guide to biotech & pharma leaders: Navigating great uncertainty and complexityIn this episode, we sit down with Murray Aitken, Executive Director of the IQVIA Institute for Human Data Science, to discuss the trends shaping the life sciences industry in 2025 and beyond.How do we navigate the life sciences industry in times of great uncertainty?Murray has observed the life sciences industry for decades and lays out his balanced perspective of the state of the industry and the underlying uncertainties, challenges and opportunities. This episode is a must-watch for anyone who wants to know what is going on in the industry. If you want t...2025-03-041h 00Cures & CapitalMike Rea on why pharma struggles with innovation - and how to fix itIn this episode, Mike Rea - CEO, IDEA Pharma - takes us on a journey through innovation and value creation in pharma. It is not all roses!He shares his candid views on what the pharmaceutical industry needs to do better to be less confused about innovation.Mike Rea also explains the importance of getting the definition of innovation right in drug development. Early commercial involvement in drug R&D is another key pillar in his drug innovation philosophy.We also get to discuss organizational design and team size conducive to unlocking pharma's...2025-02-181h 08Cures & CapitalKelvin Stott on what it takes to fix pharma's broken business modelIn this episode, Kelvin Stott talks about why might be pharma's business model broken and how can it be fixed, the declining ROI on drug R&D, better R&D portfolio decision making, raising the bar in pharma/biotech innovation and more. Kelvin Stott has over 20 years of diverse leadership experience in pharma R&D strategy and operations, drug discovery and development, portfolio management, strategy consulting, biotech start-ups and venture capital. Currently, he is the Founder and CEO of Amporin Pharmaceuticals.If you want to connect with us:Linkedin: https://www.linkedin.com/company/c...2025-02-021h 00Cures & CapitalJack Scannell on drug R&D decision-making: The value of getting it rightIn this episode, Dr. Jack Scannell delves into topics such as R&D productivity, decision-making, model validity, and more.If you're looking to deepen your understanding of these areas, there's no better guide than Jack.Jack brings a deep and holistic understanding of the biotech and pharma industry, having held a variety of roles—including being a neuroscientist, strategy consultant, investment analyst, and now the CEO of Etheros Pharmaceuticals.Chapters:00:00 Intro02:08 Guest introduction - Dr. Jack Scannell05:46 R&D productivity from past to present to future34:00 Decision making, model va...2025-01-211h 18Cures & CapitalCures & Capital: Trailer EpisodeEPISODE 1 - Cures & Capital: Trailer EpisodeIn this episode, we introduce the scope and mission of the podcast.Our focus with Cures & Capital is the intersection between drug R&D and finance. Hosts: Martin Slezak & Simon Birksø.Disclaimer: This podcast and activities related to it are completely independent from our day jobs. All the views and opinions expressed through this channel are solely our own and do not represent or in any way reflect the views and opinions of the companies we work for.2025-01-1103 min